Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis.
Although biologic therapies have changed the course of rheumatoid arthritis (RA), today's major challenge remains to identify biomarkers to target treatments to selected patient groups. Circulating micro(mi)RNAs represent a novel class of molecular biomarkers whose expression is altered in RA. Our study aimed at quantifying miR-125b in blood and serum samples from RA patients, comparing healthy controls and patients with other forms of rheumatic diseases and arthritis, and evaluating its predictive value as biomarker for response to rituximab. Detectable levels of miR-125b were measured in total blood and serum samples and were significantly elevated in RA patients compared to osteoarthritic and healthy donors. The increase was however also found in patients with other forms of chronic inflammatory arthritis. Importantly, high serum levels of miR-125b at disease flare were associated with good clinical response to treatment with rituximab three months later (P = 0.002). This predictive value was not limited to RA as it was also found in patients with B lymphomas. Our results identify circulating miR-125b as a novel miRNA over expressed in RA and suggest that serum level of miR-125b is potential predictive biomarker of response to rituximab treatment.
Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France.
Isabelle
I
Duroux-Richard
Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Clinical Department for Osteoarticular Diseases, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.
Yves-Marie
0000-0001-5927-3773
YM
Pers
Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Clinical Department for Osteoarticular Diseases, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.
Sylvie
S
Fabre
Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France.
Meryem
M
Ammari
Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Dominique
D
Baeten
Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Département d'Hématologie, CHU Saint Eloi, 80 Avenue Augustin Fliche, 34295 Montpellier, France ; UMR-CNRS 5235, Université Montpellier II, Place Eugène Bataillon, 34095 Montpellier, France.
Guillaume
G
Cartron
Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Unité des Maladies Autoinflammatoires, Laboratoire de Génétique, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.
Isabelle
I
Touitou
Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Clinical Department for Osteoarticular Diseases, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.
Christian
C
Jorgensen
Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Clinical Department for Osteoarticular Diseases, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.
Florence
F
Apparailly
D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics*; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D007249:Inflammation / Q000378:metabolism*; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D011237:Predictive Value of Tests; D000069283:Rituximab; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D015415:Biomarkers; C531888:MIRN125 microRNA, human; D035683:MicroRNAs; D000069283:Rituximab